

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Addiese: COMMISSIONER FOR PATENTS P O Box 1450 Alexandra, Virginia 22313-1450 www.wepto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/083,682	10/24/2001	Alan P. Wolffe	8325-0015.20	1541	
20855 ROBINS & P.	7590 03/08/201 ASTERNAK	EXAMINER			
1731 EMBARCADERO ROAD			ZHOU, SHUBO		
SUITE 230 PALO ALTO,	CA 94303		ART UNIT	PAPER NUMBER	
			1631		
			MAIL DATE	DELIVERY MODE	
			03/08/2010	PAPER	

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Advisory Action Before the Filing of an Appeal Brief

Application No.	Applicant(s)		
10/083,682	WOLFFE ET AL.		
Examiner	Art Unit		
SHUBO (Joe) ZHOU	1631		

	SHUBO (Joe) ZHOU	1631					
The MAILING DATE of this communication appe	ars on the cover sheet with the c	orrespondence add	ress				
THE REPLY FILED 08 February 2010 FAILS TO PLACE THIS APPLICATION IN CONDITION FOR ALLOWANCE.							
. ☑ The reply was filed after a final rejection, but prior to or on the same day as filing a Notice of Appeal. To avoid abandonment of this application, applicant must timely file one of the following replies: (1) an amendment, affidavit, or other evidence, which places the application in condition for allowance; (2) a Notice of Appeal (with appeal fee) in compliance with 3' TCR 41.31; or (3) a Request for Continued Examination (RCE) in compliance with 3' TCR 1.114. The reply must be filed within one of the following time periods:							
a) The period for reply expiresmonths from the mailing b) The period for reply expires on: (1) the mailing date of this A no event, however, will the statutory period for reply expire Is Examiner Note: If box 1 is checked, check either box (a) or (MONTHS OF THE FINAL REJECTION. See MPEP 706.07f	dvisory Action, or (2) the date set forth in ter than SIX MONTHS from the mailing b). ONLY CHECK BOX (b) WHEN THE	date of the final rejection	n.				
Extensions of time may be obtained under 37 CFR 1.136(a). The date on which the petition under 37 CFR 1.136(a) and the appropriate extension fee have been filled is the date for purposes of determining the period of extension and the corresponding encount of the fee. The appropriate extension fee have been filled is the date for purposes of determining the period of extension and the corresponding encount of the fee. The appropriate extension fee house 37 CFR 1.17(a) is calculated from: (1) the expiration date of the shortened statutory period for reply originally set in the final Office action; or (2) as set fort in (b) above, if checked. Any reply received by the Office later than three months after the mailing date of the final rejection, even if timely filed, may reduce any earned patient term adjustment. See 37 CFR 1.704(b). NOTICE OF APPEAL							
2. The Notice of Appeal was filed on A brief in compliance with 37 CFR 41.37 must be filed within two months of the date of filing the Notice of Appeal (37 CFR 41.37(a)), or any extension thereof (37 CFR 41.37(a)), to avoid dismissal of the appeal. Since a Notice of Appeal has been filed, any reply must be filed within the time period set forth in 37 CFR 41.37(a).							
AMENDMENTS							
 The proposed amendment(s) filed after a final rejection, but prior to the date of filing a brief, will not be entered because (a) They raise new issues that would require further consideration and/or search (see NOTE below); (b) They raise the issue of new matter (see NOTE below); (c) They are not deemed to place the application in better form for appeal by materially reducing or simplifying the issues for 							
appeal; and/or	er form for appear by materially rec	rucing or simplifying ti	ie issues ioi				
(d) ☐ They present additional claims without canceling a c NOTE: (See 37 CFR 1.116 and 41.33(a)).	orresponding number of finally reje	ected claims.					
4. The amendments are not in compliance with 37 CFR 1.12	1. See attached Notice of Non-Cor	mpliant Amendment (f	PTOL-324).				
Applicant's reply has overcome the following rejection(s):							
Newly proposed or amended claim(s) would be all non-allowable claim(s).		•					
7. For purposes of appeal, the proposed amendment(s): a) [how the new or amended claims would be rejected is prov The status of the claim(s) is (or will be) as follows: Claim(s) allowed:		be entered and an ex	planation of				
Claim(s) objected to: Claim(s) rejected:							
Claim(s) withdrawn from consideration: AFFIDAVIT OR OTHER EVIDENCE							
The affidavit or other evidence filed after a final action, but because applicant failed to provide a showing of good and was not earlier presented. See 37 CFR 1.116(e).							
 The affidavit or other evidence filed after the date of filing entered because the affidavit or other evidence failed to or showing a good and sufficient reasons why it is necessary 	vercome <u>all</u> rejections under appea and was not earlier presented. Se	ll and/or appellant fails ee 37 CFR 41.33(d)(1)	s to provide a				
10. The affidavit or other evidence is entered. An explanation REQUEST FOR RECONSIDERATION/OTHER		•					
 The request for reconsideration has been considered but see continuation sheet. 		condition for allowan	ce because:				
2. Note the attached Information Disclosure Statement(s). (PTO/SB/08) Paper No(s) 3. Other:							
	/SHUBO (Joe) ZHOU/ Primary Examiner, Art U	nit 1631					

Continuation of 7(b) and 11:

There appears to be no amendment made to the claims in the response filed 2/8/10.

The rejection of the claims under 35 USC 103(a) stands for the reasons set forth in the final rejection mailed 12/8/09, and applicant's arguments filed 2/8/10 have been fully considered but found unpersuasive.

It appears that applicant's arguments are on the ground that the cloning in Grosveld involves cloning a single sequence (i.e. "the target sequence") and a collection of the same polynucleotide molecules in otal Birbary. This is not found persuasive. Firstly, in a reasonably broad sense, a collection of the same polynucleotide molecules is also a library, which meets the definition of the term defined in the instant specification as "a population of DNA fragments that have been propagated in some type of a cloning vector." See paragraph [0198] of the published application. This is akin to a collection of 100 the same books in a room for people to read. This collection of books is still a library albeit maybe a small and limited library, but it is still a library in the reasonably broad sense. Secondly, as set forth in the previous Office action such as on page 6 of the final rejection mailed 12800, one of ordinary skill in the at vioual have been motivated to modify the method of Clontech and motivated by Grosveld et al. to treat the chromatin with the method of Grosveld et al. and not only cone the DNase I hypersensitive fragments directly from the fragments identified in column 8 if there are no clones readily available comprising such fragments in order to obtain such fragments with contain regulatory sequences because Grosveld et al. claim of suggest obtaining such fragments. A collection of clones containing these different fragments (which are DNase I hypersensitive, and hence the accessible regions) would also be a library.